Norgine Strengthens Rare Disease Portfolio With Theravia Acquisition
Norgine has announced that it acquired Theravia, an international pharmaceutical company specializing in treatments for patients with rare and debilitating conditions, from Mérieux Equity Partners. Theravia has several products in the rare disease space, including SIKLOS®, for adults and children with sickle cell disease, and ORPHACOL®, a medicine for adults and children who have a genetic disorder that affects bile production by the liver. The development of Theravia in the past few years has been supported by its majority shareholder Mérieux Equity Partners, a healthcare dedicated investment firm based in France. Norgine is a specialty pharmaceutical and consumer healthcare company. The... Read More »
Marubeni Acquires Sumitomo’s Asia Pharma Business for $300 Million
On April 2, Marubeni Corporation announced that it was purchasing a stake in the Asian pharmaceutical business of Sumitomo. Marubeni is purchasing a 60% stake for ¥45 billion ($300 million). After 2029, Marubeni can take on the remaining 40% stake from Sumitomo for some ¥27 billion ($180 million). There is a total enterprise value of ¥72 billion ($480 million). A purchase price of $500 million represents the 100% stake of the company. Sumitomo is a biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need in oncology, urology, women’s health, rare disease, cell and gene therapies and psychiatry and neurology.... Read More »
Mallinckrodt and Endo Agree to Combine in a Deal Valued at $6.7 Billion
Mallinckrodt plc and Endo, Inc. announced that they have entered into a definitive agreement to combine in a stock and cash transaction. Mallinckrodt will continue as the holding company for the combined business, and Endo will become a wholly-owned subsidiary of Mallinckrodt. The transaction is expected to close in the second half of 2025. In this deal, the upfront purchase price is $80 million, representing the cash payment to Endo shareholders, while they also receive a 49.9% stake in the combined company, with Mallinckrodt shareholders holding 50.1%. The combined entity has an implied pro forma enterprise value of $6.7 billion. Endo is a diversified specialty pharmaceutical company... Read More »
Kelso Pharma Acquires Alturix Holdings
On February 20, Kelso Pharma announced that it entered into an agreement to acquire Alturix Holdings for an undisclosed price. Alturix Holdings is a pharmaceutical manufacturing company based in Milton Keynes, England. In 2020, Alturix was formed following the acquisition of two family-owned pharmaceutical businesses: HK Pharma and Atlantic Pharma. Kelso Pharma is committed to bringing specialty medicines to the European healthcare markets. Kelso Pharma is backed by the healthcare specialist private equity investor Apposite Capital. This is Kelso Pharma’s third acquisition and its first in 2025. In November 2023, it purchased Velit Biopharma, a biotechnology company and... Read More »
2025 Kicks off With Several Big Biopharma Deals
With the JP Morgan 43rd Annual Healthcare Conference underway in San Francisco this week, the Biotechnology and Pharmaceutical (Biopharma) sectors are seeing a flurry of activity. Many large-scale acquisitions and licensing agreements are being announced, setting the tone for an eventful year ahead in the industry. So far this year, 14 Biopharma deals have been announced (as of January 15, 2025). Deal values have reached $15.7 billion, a significant increase from the same period in recent years. During the same time frame in 2024, there were also 14 Biopharma deals announced, but their combined value was just $4 billion. Looking back to 2023, the first two weeks saw 17 Biopharma deals, but... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
